CaPTHymone

CaPTHymone is an oral formulation of the parathyroid hormone (PTH) 1-34 fragment, developed by the Australian biotechnology company Bone Medical Limited. Designed as a non-invasive alternative to injectable osteoporosis treatments like Forteo (teriparatide), CaPTHymone utilizes a specialized oral delivery technology to allow the biologic peptide to enter the bloodstream. Its mechanism of action involves the up-regulation of osteoblasts, which stimulates new bone formation and helps regulate calcium levels. The drug was primarily investigated for the treatment and prevention of osteoporosis, Paget's disease, and other bone-related disorders. Although Phase 1 clinical trials demonstrated successful systemic absorption and biological activity, development appears to have ceased, as evidenced by the abandonment of its trademark in 2010.

Brand names

CaPTHymone

Other names

oral parathyroid hormoneoral PTH 1-34PTH 1-34 fragmentPTH1-34 fragmentPTH-1-34 fragment